Reich K, Kabashima K, Peris K, et al. - Researchers conducted this randomized clinical trial to evaluate the effectiveness and safety of 4 mg and 2 mg of baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, in combination with background topical corticosteroid (TCS) therapy in adults with moderate to severe atopic dermatitis (AD) who previously had an inadequate response to topical corticosteroid (TCS) therapy. Study participants (n = 329; mean [SD] age, 33.8 [12.4] years; 216 [66%] male) were randomly assigned (1:1:1) to receive 2 mg of baricitinib once daily (n = 109), 4 mg of baricitinib once daily (n = 111), or placebo (n = 109) for 16 weeks. In combination with background TCS therapy, a 4 mg dose of baricitinib significantly improved the signs and symptoms of moderate to severe AD, with a safety profile consistent with previous studies of baricitinib in AD. Nasopharyngitis, upper respiratory tract infections, and folliculitis were the most common adverse events.